The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

C, MPAS, wrote about how stigma and misconceptions were creating barriers to GLP-1 obesity medication uptake, on top of ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

The FDA has approved PureTech Health’s ‘space ... the pharmaceutical company whose products have emerged as the biggest selling anti-obesity drugs. In contrast, PureTech said Plenity is ...

Liraglutide is under clinical development by Novo Nordisk and currently in Phase III for Obesity. According to GlobalData, Phase III drugs for Obesity have a 44% phase transition success rate (PTSR) ...

has approved Zepbound, a prescription weight-loss medication, as the first drug specifically for treating moderate to severe obstructive sleep apnea (OSA) in people with obesity. This ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications ... on the market that the FDA has specifically approved to treat obesity — Wegovy ...

LUPKIN: You know, it could, because the FDA just approved Zepbound as the first drug treatment for moderate to severe obstructive sleep apnea in patients who have obesity. Obstructive sleep apnea is a ...